ADMA Biologics
ADMA
105 hedge funds and large institutions have $85.4M invested in ADMA Biologics in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 25 reducing their positions, and 17 closing their positions.
59% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 17
40% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 25
11% more funds holding
Funds holding: 95 → 105 (+10)
4% less capital invested
Capital invested by funds: $88.8M → $85.4M (-$3.4M)
7.72% less ownership
Funds ownership: 47.75% → 40.03% (-7.7%)
60% less call options, than puts
Call options by funds: $1.53M | Put options by funds: $3.79M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$14.9M |
| 2 |
MS
Maven Securities
St Helier,
Jersey
|
+$1.72M |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.24M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.11M |
| 5 |
Squarepoint
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$4.86M |
| 2 |
6CM
683 Capital Management
New York
|
-$3.9M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$3.04M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$1.36M |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$1.22M |
ADMA Hedge Fund Activity: Q1 2021 in Review
105 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2021, worth a combined $85.4M — down 3.8% from $88.8M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ADMA positions and 17 closed out — a net gain of 10 holders — while 35 added to existing stakes and 25 trimmed.
The largest buyer was Nuveen, adding an estimated $14.9M. The largest seller was Marshall Wace, exiting entirely with an estimated $4.86M sold.
- 105 institutional investors held ADMA Biologics (ADMA) as of Q1 2021, up from 95 in Q4 2020.
- Funds reported $85.4M of ADMA Biologics stock for Q1 2021, down 3.8% quarter-over-quarter.
- 27 funds opened new ADMA Biologics positions in Q1 2021 and 17 closed out, a net change of +10 holders.
- The largest ADMA Biologics buyer in Q1 2021 was Nuveen, an estimated $14.9M added.
- The largest ADMA Biologics seller in Q1 2021 was Marshall Wace, an estimated $4.86M sold.
Based on aggregated 13F filings for Q1 2021.